Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (180)	12/1/1998 12:47:00 PM
From: Rudy Saucillo	Read Replies (4) \| Respond to of 804

Celgene will have quite a presence at the upcoming American Society of Hematology meeting. In addition to new data on GvHD, researchers will present very important results from a trial studying use of thalidomide as a treatment for multiple myeloma (an extremely dangerous blood cancer). This is a follow-up study to the smaller, initial study that was presented in Sept. See biz.yahoo.com for info on the initial study. Here's some info on Monday's presentation (the abstract is at ex2.excerptamedica.com Abstract #1306 - 8:45, Monday, December 7, 1998 - Room B214-218 TREATMENT OF MULTIPLE MYELOMA MARKED ANTI-TUMOR EFFECT FROM ANTI-ANGIOGENESIS (AA) THERAPY WITH THALIDOMIDE (T) IN HIGH RISK REFRACTORY MULTIPLE MYELOMA (MM) S. Singhal, J. Mehta, P. Eddlemon, P. Gray, J. Cromer, R. Desikan, D. Ayers, D. Siegel, N. Munshi, E. Anaissie, H. Kantarjian, J. Zeldis, B. Barlogie Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas; University of Texas MD Anderson Cancer Center, Houston, Texas; Celgene Corporation, Warren, New Jersey, USA The abstract concludes: "In conclusion, T [thalidomide] has remarkable anti-tumor activity in advanced and high risk MM, justifying its incorporation into combination chemotherapy trials (D.T. PACE-Dex, T, cisplatin, 1 Adria, CTX, VP16) which has induced 3 true CR's [complete remissions] after 1 cycle among 5 currently evaluable patients." Rudy